Werner Cautreels - 18 Feb 2025 Form 4 Insider Report for Traws Pharma, Inc. (TRAW)

Role
Chief Executive Officer, Director
Signature
/s/ Werner Cautreels
Issuer symbol
TRAW
Transactions as of
18 Feb 2025
Net transactions value
+$963
Form type
4
Filing time
19 Feb 2025, 18:23:35 UTC
Previous filing
27 Jan 2025
Next filing
23 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRAW Common Stock Options Exercise $963 +96,348 +1204% $0.0100 104,348 18 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRAW Pre-Funded Warrant (right to buy) Options Exercise $0 -96,348 -100% $0.000000 0 18 Feb 2025 Common Stock 96,348 $0.0100 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Common Stock was acquired by way of an exercise of Pre-Funded Warrants at an exercise price of $0.01 per Pre-Funded Warrant. The Pre-Funded warrants were acquired as part of Class B Units, with each Class B unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.
F2 The Pre-Funded Warrants became exercisable upon stockholder approval on February 17, 2025.
F3 The Pre-Funded Warrants do not expire.